193 related articles for article (PubMed ID: 37625402)
1. Tumor immunogenicity dictates reliance on TCF1 in CD8
Escobar G; Tooley K; Oliveras JP; Huang L; Cheng H; Bookstaver ML; Edwards C; Froimchuk E; Xue C; Mangani D; Krishnan RK; Hazel N; Rutigliani C; Jewell CM; Biasco L; Anderson AC
Cancer Cell; 2023 Sep; 41(9):1662-1679.e7. PubMed ID: 37625402
[TBL] [Abstract][Full Text] [Related]
2. Antigen dominance hierarchies shape TCF1
Burger ML; Cruz AM; Crossland GE; Gaglia G; Ritch CC; Blatt SE; Bhutkar A; Canner D; Kienka T; Tavana SZ; Barandiaran AL; Garmilla A; Schenkel JM; Hillman M; de Los Rios Kobara I; Li A; Jaeger AM; Hwang WL; Westcott PMK; Manos MP; Holovatska MM; Hodi FS; Regev A; Santagata S; Jacks T
Cell; 2021 Sep; 184(19):4996-5014.e26. PubMed ID: 34534464
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
4. Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy.
Maniar R; Wang PH; Washburn RS; Kratchmarov R; Coley SM; Saqi A; Pan SS; Hu J; Shu CA; Rizvi NA; Henick BS; Reiner SL
Cancer Immunol Res; 2023 Feb; 11(2):164-170. PubMed ID: 36512052
[TBL] [Abstract][Full Text] [Related]
5. LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy.
Sun L; Ma Z; Zhao X; Tan X; Tu Y; Wang J; Chen L; Chen Z; Chen G; Lan P
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272565
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
7. Differential Requirements for Tcf1 Long Isoforms in CD8
Gullicksrud JA; Li F; Xing S; Zeng Z; Peng W; Badovinac VP; Harty JT; Xue HH
J Immunol; 2017 Aug; 199(3):911-919. PubMed ID: 28652395
[TBL] [Abstract][Full Text] [Related]
8. Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control.
Detrés Román CR; Rudloff MW; Revetta F; Favret NR; Murray KA; Roetman JJ; Erwin MM; Washington MK; Philip M
bioRxiv; 2024 Feb; ():. PubMed ID: 38464229
[TBL] [Abstract][Full Text] [Related]
9. The Potential of T Cell Factor 1 in Sustaining CD8
Jung S; Baek JH
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33572793
[TBL] [Abstract][Full Text] [Related]
10. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.
Wang Y; Ma L; Chen Y; Yun W; Yu J; Meng X
Cancer Sci; 2024 Apr; ():. PubMed ID: 38590234
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Reactive CD8+ T Cells Enter a TCF1+PD-1- Dysfunctional State.
Roetman JJ; Erwin MM; Rudloff MW; Favret NR; Detrés Román CR; Apostolova MKI; Murray KA; Lee TF; Lee YA; Philip M
Cancer Immunol Res; 2023 Dec; 11(12):1630-1641. PubMed ID: 37844197
[TBL] [Abstract][Full Text] [Related]
14. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
O'Melia MJ; Manspeaker MP; Thomas SN
Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral-based vaccine promotes neoantigen-specific CD8
D'Alise AM; Brasu N; De Intinis C; Leoni G; Russo V; Langone F; Baev D; Micarelli E; Petiti L; Picelli S; Fakih M; Le DT; Overman MJ; Shields AF; Pedersen KS; Shah MA; Mukherjee S; Faivre T; Delaite P; Scarselli E; Pace L
Sci Transl Med; 2022 Aug; 14(657):eabo7604. PubMed ID: 35947675
[TBL] [Abstract][Full Text] [Related]
16. Human CXCR5
Hofland T; Martens AWJ; van Bruggen JAC; de Boer R; Schetters S; Remmerswaal EBM; Bemelman FJ; Levin MD; Bins AD; Eldering E; Kater AP; Tonino SH
Eur J Immunol; 2021 Mar; 51(3):703-713. PubMed ID: 33098668
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive profile of TCF1
Wang D; Fang J; Wen S; Li Q; Wang J; Yang L; Dai W; Lu H; Guo J; Shan Z; Xie W; Liu X; Wen L; Shen J; Wang A; Chen Q; Wang Z
Int J Oral Sci; 2022 Feb; 14(1):8. PubMed ID: 35153298
[TBL] [Abstract][Full Text] [Related]
18. Ectopic Tcf1 expression instills a stem-like program in exhausted CD8
Shan Q; Hu S; Chen X; Danahy DB; Badovinac VP; Zang C; Xue HH
Cell Mol Immunol; 2021 May; 18(5):1262-1277. PubMed ID: 32341523
[TBL] [Abstract][Full Text] [Related]
19. TCF1 in T cell immunity: a broadened frontier.
Zhao X; Shan Q; Xue HH
Nat Rev Immunol; 2022 Mar; 22(3):147-157. PubMed ID: 34127847
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Tcf1 by Inflammatory Cytokines Facilitates Effector CD8 T Cell Differentiation.
Danilo M; Chennupati V; Silva JG; Siegert S; Held W
Cell Rep; 2018 Feb; 22(8):2107-2117. PubMed ID: 29466737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
